HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Robitussin Gets Natural With Honey, Ivy Leaf, Eucalyptus Supplements For Cough Relief

Executive Summary

GSK launches Robitussin Naturals drug-free cough and cold remedies in the first naturals offering under the top-selling OTC drug brand. The line includes liquids and gummies for adults and children formulated with honey, ivy leaf and eucalyptus.

You may also be interested in...

Mucinex Children’s FreeFrom; PURA CBD For Pets, Sweets and Lovers; Health & Wellness Product News

Reckitt Benckiser extends its Mucinex FreeFrom cold and flu line into children’s products, offering OTC active ingredients but without additives, artificial colors, flavors and sugar. Applied Biological Laboratories touts research suggesting its new Biovanta throat lozenges and sprays with aspirin and natural ingredients such as honey can help control upper respiratory inflammation. News in brief.

J&J Producing Tylenol ‘24-7’ As US OTC Sales Jump 35% On Pandemic-Driven Stockpiling

J&J is prioritizing Tylenol production on caplets easiest to manufacture to maximize output as it manufactures the line around the clock, says CEO Alex Gorsky. First-quarter US OTC sales soared 35% as consumers stockpiled due to COVID-19, though the pandemic led J&J to downgrade its 2020 outlook.

Natural OTCs prepare for lift off

Increasing demand for more natural products is opening up an enticing opportunity for consumer healthcare players.Tom Gallen explores the tools firms can use to make their brands stand out in this growing market.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts